Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects With and Without Atopic Dermatitis

被引：0
|
作者：
Davis, Carla M. [1 ]
Green, Todd David [2 ]
Lambert, Romain [3 ]
Fleischer, David [4 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] UPMC, Childrens Hosp Pittsburgh, 4401 Penn Ave, Pittsburgh, PA USA
[3] DBV Technol, Montrouge, France
[4] Childrens Hosp Colorado, Aurora, CO USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2019年 / 143卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2018.12.740
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
735
引用
收藏
页码：AB242 / AB242
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study
    Scurlock, Amy
    Bee, Katharine
    Sampson, Hugh
    Meney, Jonas
    Bahnson, Henry
    Burks, A. Wesley
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB28 - AB28
  • [2] Efficacy and safety of epicutaneous immunotherapy (EPIT) for peanut allergy in subjects with and without concomitant food allergies
    Begin, P.
    Sussman, G.
    Beyer, K.
    Oriel, R. C.
    Ford, L.
    Shreffler, W.
    Campbell, D. E.
    Green, T. D.
    Mukherjee, R.
    Fleischer, D. M.
    ALLERGY, 2020, 75 : 49 - 50
  • [3] Six months Epicutaneous Immunotherapy in peanut allergy: safety and efficacy
    Dupont, C.
    Bourrier, T.
    de Blay, F.
    Guenard, L.
    Castelain, M.
    Cousin, M.
    Sauvage, C.
    Kanny, G.
    Jarlot, S.
    Karila, C.
    ALLERGY, 2012, 67 : 600 - 600
  • [4] Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy
    Dupont, Christophe
    Burks, A. Wesley
    Fleischer, David M.
    Bee, Katharine J.
    Chainani, Sarita
    Sampson, Hugh A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (06) : 623 - 633
  • [5] Safety and efficacy of epicutaneous immunotherapy for peanut allergic children with and without asthma
    Lange, L.
    Agbotounou, W.
    Lambert, R.
    Fleischer, D. M.
    Pongracic, J. A.
    ALLERGY, 2019, 74 : 332 - 333
  • [6] Efficacy and safety of epicutaneous immunotherapy (EPIT) for peanut allergy in subjects aged 1-3 years with and without concomitant asthma in the epitope study
    du Toit, G.
    Trujillo, J.
    Arends, N.
    Vogelberg, C.
    Turner, P.
    Bois, T.
    Campbell, D. E.
    Bee, K.
    Sampson, H.
    Burks, A. W.
    ALLERGY, 2023, 78
  • [7] Safety and efficacy of epicutaneous immunotherapy for food allergy
    Wang, Julie
    Sampson, Hugh A.
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2018, 29 (04) : 341 - 349
  • [8] Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Concomitant Food Allergies in the EPITOPE Study
    Fleischer, David
    Green, Todd
    Sampson, Hugh
    Meney, Jonas
    Bahnson, Henry
    Burks, A. Wesley
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB27 - AB27
  • [9] Epicutaneous immunotherapy against peanut allergy
    Pettersen, Petter Morten
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2019, 139 (08) : 708 - 708
  • [10] Epicutaneous immunotherapy for the treatment of peanut allergy
    Ravindran, Mayuran
    Sampson, Hugh A.
    Kim, Edwin H.
    Bee, Katharine J.
    Green, Todd D.
    Burks, A. Wesley
    ALLERGY, 2025, 80 (01) : 63 - 76
12345